Studies on the role of dopamine in the degeneration of 5‐HT nerve endings in the brain of Dark Agouti rats following 3,4‐methylenedioxymethamphetamine (MDMA or ‘ecstasy’) administration
- 1 February 1999
- journal article
- Published by Wiley in British Journal of Pharmacology
- Vol. 126 (4), 911-924
- https://doi.org/10.1038/sj.bjp.0702373
Abstract
1. We investigated whether dopamine plays a role in the neurodegeneration of 5-hydroxytryptamine (5-HT) nerve endings occurring in Dark Agouti rat brain after 3,4-methylenedioxymethamphetamine (MDMA or 'ecstasy') administration. 2. Haloperidol (2 mg kg(-1) i.p.) injected 5 min prior and 55 min post MDMA (15 mg kg(-1) i.p.) abolished the acute MDMA-induced hyperthermia and attenuated the neurotoxic loss of 5-HT 7 days later. When the rectal temperature of MDMA + haloperidol treated rats was kept elevated, this protective effect was marginal. 3. MDMA (15 mg kg(-1)) increased the dopamine concentration in the dialysate from a striatal microdialysis probe by 800%. L-DOPA (25 mg kg(-1) i.p., plus benserazide, 6.25 mg kg(-1) i.p.) injected 2 h after MDMA (15 mg kg(-1)) enhanced the increase in dopamine in the dialysate, but subsequent neurodegeneration was unaltered. L-DOPA (25 mg kg(-1)) injected before a sub-toxic dose of MDMA (5 mg kg(-1)) failed to induce neurodegeneration. 4. The MDMA-induced increase in free radical formation in the hippocampus (indicated by increased 2,3- and 2,5-dihydroxybenzoic acid in a microdialysis probe perfused with salicylic acid) was unaltered by L-DOPA. 5. The neuroprotective drug clomethiazole (50 mg kg(-1) i.p.) did not influence the MDMA-induced increase in extracellular dopamine. 6. These data suggest that previous observations on the protective effect of haloperidol and potentiating effect of L-DOPA on MDMA-induced neurodegeneration may have resulted from effects on MDMA-induced hyperthermia. 7. The increased extracellular dopamine concentration following MDMA may result from effects of MDMA on dopamine re-uptake, monoamine oxidase and 5-HT release rather than an 'amphetamine-like' action on dopamine release, thus explaining why the drug does not induce degeneration of dopamine nerve endings.Keywords
This publication has 69 references indexed in Scilit:
- Role of hyperthermia in the protective action of clomethiazole against MDMA (‘ecstasy’)‐induced neurodegeneration, comparison with the novel NMDA channel blocker AR‐R15896ARBritish Journal of Pharmacology, 1998
- Carrier‐dependent and Ca2+‐dependent 5‐HT and dopamine release induced by (+)‐amphetamine, 3,4‐methylendioxy‐methamphetamine, p‐chloroamphetamine and (+)‐fenfluramineBritish Journal of Pharmacology, 1997
- Estimating Hydroxyl Radical Content in Rat Brain Using Systemic and Intraventricular Salicylate: Impact of MethamphetamineJournal of Neurochemistry, 1995
- Hydroxylation of salicylate as an assay for hydroxyl radicals: A cautionary noteFree Radical Biology & Medicine, 1991
- Acute effects of 3,4-methylenedioxymethamphetamine (MDMA) on monoamines in rat caudatePharmacology Biochemistry and Behavior, 1991
- Neurotoxicity of MDMA and Related Compounds: Anatomic StudiesaAnnals of the New York Academy of Sciences, 1990
- Neurotoxicity of MDMA: Neurochemical EffectsAnnals of the New York Academy of Sciences, 1990
- MDMA: Historical PerspectivesAnnals of the New York Academy of Sciences, 1990
- Ketanserin pretreatment attenuates MDMA-induced dopamine release in the striatum as measured by microdialysisLife Sciences, 1990
- CNS stimulants: two distinct mechanisms of action for amphetamine-like drugsTrends in Pharmacological Sciences, 1983